Biotech firm Mabpharm tests Hong Kong listing

unilab_Adobe_230x150
By Jonathan Breen
11 Mar 2019

China-based biotechnology firm Mabpharm is looking for the greenlight to list in Hong Kong, having filed a draft IPO prospectus with the city’s stock exchange.

The pre-revenue company focuses on the Chinese market, covering cancers and autoimmune diseases, pursuing research and development for the production of drugs and biosimilars.

It has nine monoclonal antibody drugs — treatments that use natural immune system functions to fight diseases — among which are three of its ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access: subs@globalcapital.com

Or sign up for a trial to gain full access to the entire site for a limited period.

Free Trial

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: subs@globalcapital.com or find out more online here.